Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-03-05 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2017年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2017 Annual General Meeting (AGM) resolution announcement for 哈药集团股份有限公司. It details the date and location of the meeting, attendance, voting results on various agenda items including the 2017 annual report, board and supervisory reports, financial budget, profit distribution plan, auditor appointment, and amendments to the company articles. It also includes lawyer verification of the meeting's legality and validity. The document is a formal announcement of the resolutions passed at the AGM, not the full annual report itself. The length is about 4047 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-03-05 Chinese
2017年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2017 Annual General Meeting (AGM) of Harbin Pharmaceutical Group Co., Ltd. It details the procedures of convening and holding the AGM, the qualifications of attendees, the voting procedures, and the voting results. The document explicitly states it is a legal opinion on the AGM process and voting results, not the AGM materials themselves or the annual report. The document is not the annual report (10-K) or the voting results announcement (DVA) but a legal opinion related to the AGM. Given the content and purpose, this document fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting. The document length (6022 characters) and detailed content support this classification with high confidence.
2018-03-05 Chinese
2017年年度股东大会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the 2017 Annual General Meeting (AGM) of 哈药集团股份有限公司, dated March 5, 2018. It includes detailed agenda items such as the 2017 Annual Report full text and summary, board of directors' work report, supervisory board report, financial statements and budget proposals, profit distribution plan, audit report summary and reappointment of the accounting firm, bank credit application, independent directors' reports, and amendments to company articles. The content is comprehensive and includes substantive financial data, management reports, audit summaries, and governance-related information, all typical of AGM meeting materials. The document is not merely an announcement or a brief summary but contains detailed reports and proposals to be discussed and voted on at the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2018-02-26 Chinese
关于终止重大资产重组事项投资者说明会召开情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the holding of an investor conference call about the termination of a major asset restructuring plan. It details the date and time of the investor meeting, participants, questions raised by investors, and the company's responses. The content focuses on communication with investors about the termination of a major asset restructuring and related investment plans, rather than presenting financial statements or detailed financial results. The document length is 4564 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or comprehensive financial analysis present. The document is clearly an announcement about the investor meeting and the termination of the major asset restructuring, not the restructuring report itself or a financial report. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general regulatory announcement and investor communication that does not fit other specific categories.
2018-02-26 Chinese
关于公司股票复牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the resumption of trading of the company's stock after a suspension due to a major asset restructuring process that was ultimately terminated. It includes references to previous announcements and investor meetings but does not contain financial statements or detailed financial data. The document length is only 1100 characters, which is quite short and consistent with an announcement rather than a full report. The content focuses on the status of the stock suspension and resumption, which is typical of a Regulatory Filing (RNS) or possibly a Capital/Financing Update (CAP). However, since the document mainly announces the resumption of trading and termination of a restructuring process without detailed financing or capital structure changes, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. Therefore, the classification is RNS with high confidence.
2018-02-26 Chinese
更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement related to a previous announcement about a major asset restructuring transaction. It clarifies details about the transaction approval process and termination fees. The document is short (1093 characters) and serves to correct and update information previously disclosed. It does not contain financial statements, detailed financial data, or comprehensive report content. It is an announcement correcting a prior disclosure, not a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and corrections that do not fit other specific categories.
2018-02-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.